| Literature DB >> 19009037 |
Abstract
In this overview the influence of functional bladder disturbances and of its treatment on the resolution of vesicoureteral reflux (VUR) in children is discussed. Historically both bladder dysfunction entities, the overactive bladder (OAB) and the dysfunctional voiding (DV), have been described in conjunction with VUR. Treatment of the dysfunction was also considered to influence spontaneous resolution in a positive way. During the last decades, however, papers have been published which could not support these results. Regarding the OAB, a prospective study with treatment of the bladder overactivity with anticholinergics, did not influence spontaneous resolution rate in children with a dysfunction including also the voiding phase, DV and DES (dysfunctional elimination syndrome), most studies indicate a negative influence on the resolution rate of VUR in children, both before and after the age for bladder control, both with and without treatment. However, a couple of uncontrolled studies indicate that there is a high short-term resolution rate after treatment with flow biofeedback. It should be emphasized that the voiding phase dysfunctions (DV and DES) are more severe than the genuine filling phase dysfunction (OAB), with an increased frequency of UTI and renal damage in the former groups. To be able to answer the question if treatment of bladder dysfunction influence the resolution rate of VUR in children, randomized controlled studies must be performed.Entities:
Year: 2008 PMID: 19009037 PMCID: PMC2581743 DOI: 10.1155/2008/815472
Source DB: PubMed Journal: Adv Urol ISSN: 1687-6369
Prevalence of bladder dysfunction in patients with VUR.
| Reference | Age (years) | Patients with VUR (number) | Bladder dysfunction (% of total) | Overactive bladder (% of total) | Dysfunctional voiding (% of total) | Dysfunctional elimination syndrome (% of total) | ||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Snodgrass
1991 [ | 0.1/16 | 39 | 20% | |||||
| Van Gool et al. 1992 [ | 310 | 18% | 8% | 6% | ||||
| Snodgrass
1998 [ | 3–10 | 128 | 52% | |||||
| Homayoon et al. 2005 [ | >3.5–4 | 342 | 20% | |||||
|
| ||||||||
|
| ||||||||
| Taylor et al. 1982 [ | 4–15 | 37 | 75% | 75% | ||||
| Koff & Murtagh 1983 [ | 2–14 | 62 | 55% | 55% | ||||
| Griffiths & Scholtmeijer 1987 [ | 2–15 | 104 | **25% (23%) | **14% (25%) | ||||
| Scholtmeijer & Nijman 1994 [ | 0.1–15 | 101 | 38% | 38% | ||||
| Koff et al. 1998
[ | after bladder control | 143 | 46% | 27% | 23% | 46% | ||
| Yeung et
al., 2006 [ | 1–11 | 82 | 55% | *38 | *27 | |||
*% of those with bladder dysfunction, **in brackets additional number with OAB and dysfunctional voiding, respectively, but with some uncertainty of the diagnosis.
Impact of treatment of bladder dysfunction on spontaneous resolution of VUR.
| Reference | Age (y) | Patients (number) | VUR grade | Bladder dysfunction | Treatment | Follow/up (y) | Resolution (downgrading) | Controls resolution (downgrading) |
|---|---|---|---|---|---|---|---|---|
| Koff &
Murtagh 1983 [ | 2–14 | 62 | I-IV | OAB | Anticholonergics | 4 | 44% (16%) | 17% (0%) |
| Scholtmeijer
& Griffiths 1990 [ | 25 | I-IV | OAB | Anticholinergics | 1 | 37% (22%) | No controls | |
| Scholtmeijer
& Nijman 1994 [ | 0.1–15 | 39 | I-IV | OAB | Anti-cholinergics | 3 | 38% (38%) | 40% (16%) |
| Willemsen
& Nijman 2000 [ | 0.1–15 | 102 | I-V | OAB | Anti-cholinergics | 5 | 51% | 55% |
| Palmer
et al. 2002 [ | 6–10 | 25 | I-III | DV | Biofeedback | 1 | 55% (16%) | No controls |
| Kibar
et al. 2007 [ | 7.2 | 78 | I-IV | DV | Biofeedback | 0.5 | 63% (29%) | No controls |
| Homsy 1985
[ | 4–11 | 35 | I-IV | OAB + DV | Oxybutynine | 2.5 | 50% (22%) | No controls |
| Snodgrass
1998 [ | 3–10 | 128 | OAB + DV | Oxybutynine | 45% | 61% |
Prevalence of VUR in patients with bladder dysfunction. Urodynamic studies.
| Reference | Age (years) | Patients with bladder dysfunction (number) | Overactive bladder (% of patients with VUR) | Dysfunctional voiding (% of patients with VUR) | Patients with VUR (% of total) |
|---|---|---|---|---|---|
|
*Koff
et al. 1979 [ | 2.5–17 | 53 | 100% | 47% | |
| Hoebeke
et al. 2001 [ | 9–10 | 1000 | 58% | 31% | 14% |
| Ural
et al. 2008 [ | 1.5–15 | 340 | 71% | 6% | 46% |
*Only patients with UTI included.